Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis

BACKGROUND: Brain metastases (BMs) are frequent events in patients with HER2-positive metastatic breast cancer (MBC) and are associated with poor prognosis. Small-molecule anti-HER2 tyrosine kinase inhibitors (TKIs) are promising agents for the treatment of BM. In this study, we assess the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Nader-Marta, G., Martins-Branco, D., Agostinetto, E., Bruzzone, M., Ceppi, M., Danielli, L., Lambertini, M., Kotecki, N., Awada, A., de Azambuja, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160675/
https://www.ncbi.nlm.nih.gov/pubmed/35653982
http://dx.doi.org/10.1016/j.esmoop.2022.100501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160675/
https://www.ncbi.nlm.nih.gov/pubmed/35653982
http://dx.doi.org/10.1016/j.esmoop.2022.100501

Ejemplares similares